During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV), outperforming the Russell 3000® Growth Health Care ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development.

Medicamen Organics Limited has announced impressive financial results for FY25, showcasing strong performance across key ...

The beauty industry is undergoing a significant transformation, driven by scientific advances, evolving consumer expectations ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $86.75, with a ...

Biotech firm Revvity ( RVTY) posted first-quarter results that topped analysts' estimates. The company on Monday reported adjusted earnings of $1.01 per share on revenue of $664.76 million, above the ...

"China's biotechnology sector thrives on a dual engine ... giants stems partly from the remarkable global market performance of its homegrown innovative drugs. Akeso Inc, a startup based ...

Many experts rank BMRN as one of the most profitable stocks in the biotech industry due to its solid financial performance and potential for future growth. The company is working on its ...

BIOG’s performance has been particularly challenging as the managers favour emerging (less mature) biotech companies, which have fared particularly poorly versus the S&P 500 during the longest and ...